ArticleScientific reports2025
Downregulation of UDP-glucose 6-dehydrogenase predicts adverse outcomes in patients with colorectal cancer and promotes tumorigenesis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Tol-Pal System Promotes Pseudoiodinine Production by Enhancing Bacterial Growth inMicroorganisms · 2026Article
- Transcriptional Activity of Genes Related to the Biotransformation Process in the Development of Colorectal Cancer.International journal of molecular sciences · 2025Article
- Uridine diphosphate-glucose 6-dehydrogenase-mediated glucuronidation and its emerging role in gut-liver immune regulation.World journal of gastrointestinal oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
UDP-glucose 6-dehydrogenase (UGDH) is the key enzyme of glucuronic acid metabolism and a key mediator in several cancer developmental signaling pathways. However, the expression and function of UGDH in colorectal cancer (CRC) are unclear. Bioinformatics analysis was conducted to research the expression, diagnosis, prognosis, functional enrichment, genetic alterations, and immune characteristics of UGDH in CRC. Hematoxylin-Eosin staining, KI67 immunohistochemistry staining, and UGDH immunohistochemistry staining of clinical colon tissues were performed. The UGDH gene was knocked down in HCT-8 cells. CCK8 and cell wound scratch assays were further performed in UGDH wild-type and UGDH-knockdown HCT-8 cells. UGDH is markedly downregulated in CRC tissues compared to normal tissues, which predicts a poor prognosis. The lower expression of UGDH is associated with a high gene promoter methylation level and genome deletion. UGDH expression is proportional to immune cell infiltration and immune-related genes. UGDH expression is correlated with the p53 signaling pathway. Knockdown of UGDH in HCT-8 cells promoted their proliferation and migration ability. UGDH could be useful as a valuable prognostic biomarker and potential therapeutic target in CRC. UGDH could inhibit the proliferation and migration of CRC cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.